Praxis Precision Medicines, Inc. PRAX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $284.3M+6.4% | $267.12M+8.6% | $245.9M+10.8% | $221.98M+19.2% | $186.24M+22.2% | ||
| $73.03M+23.6% | $59.08M+8.1% | $54.68M-4.7% | $57.37M+4.5% | $54.89M-2.5% | ||
| $357.33M+9.5% | $326.2M+8.5% | $300.57M+7.6% | $279.35M+15.9% | $241.13M+15.5% | ||
| -$357.33M-9.5% | -$326.2M-11.3% | -$293.11M-7.9% | -$271.59M-16.6% | -$233.01M-16.4% | ||
| $30.8M+34.3% | $22.93M+14.2% | $20.07M-2.4% | $20.57M+0.6% | $20.45M+17.9% | ||
| -$326.53M-7.7% | -$303.27M-11.1% | -$273.04M-8.8% | -$251.01M-18.1% | -$212.56M-16.3% | ||
| -$13.38+0.7% | -$13.47-3.9% | -$12.96-4.9% | -$12.35-14.6% | -$10.78-4.4% | ||
| -$357.2M-9.6% | -$326.06M-11.3% | -$292.95M-8.0% | -$271.35M-16.6% | -$232.71M-16.5% | ||
| -$357.33M-9.5% | -$326.2M-11.3% | -$293.11M-7.9% | -$271.59M-16.6% | -$233.01M-16.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Praxis Precision Medicines, Inc. profitable?
- Praxis Precision Medicines, Inc. is not currently profitable: it reported a net loss of $326.5M over the trailing twelve months, a -3658.5% net margin.
- What is Praxis Precision Medicines, Inc.'s earnings per share?
- Praxis Precision Medicines, Inc.'s diluted EPS over the trailing twelve months is $-13.38.
- Where does Praxis Precision Medicines, Inc.'s income statement data come from?
- Every line is extracted from Praxis Precision Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.